enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Eluxadoline - Wikipedia

   en.wikipedia.org/wiki/Eluxadoline

   Eluxadoline, sold under the brand names Viberzi and Truberzi, [3] is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). [4] It was approved for use in the United States in 2015. [5] The drug originated from Janssen Pharmaceutica and was ...

3. Irritable bowel syndrome - Wikipedia

   en.wikipedia.org/wiki/Irritable_bowel_syndrome

   IBS can be classified as diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), with mixed/alternating stool pattern (IBS-M/IBS-A) or pain-predominant. [104] In some individuals, IBS may have an acute onset and develop after an infectious illness characterized by two or more of: fever, vomiting, diarrhea, or positive stool culture ...

4. Alosetron - Wikipedia

   en.wikipedia.org/wiki/Alosetron

   Alosetron, sold under the brand name Lotronex among others, is a 5-HT 3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only. It was patented in 1987 and approved for medical use in 2002. [2] It is currently marketed by Prometheus Laboratories Inc. .

5. Talk: What You Need to Know About the 4 Types of IBS - AOL

   www.aol.com/talk-know-4-types-ibs-200000640.html

   Explaining the difference between the four types of irritable bowel syndrome (IBS-D, IBS-C, IBS-M, IBS-U) and how the symptoms and treatments vary.

6. Lubiprostone - Wikipedia

   en.wikipedia.org/wiki/Lubiprostone

   For subjects with irritable bowel syndrome with constipation: Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea. Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea. Less common adverse reactions: <1% [3]

7. Rome process - Wikipedia

   en.wikipedia.org/wiki/Rome_process

   The Rome criteria are achieved and finally issued through a consensual process, using the Delphi method (or Delphi technique). The Rome Foundation process is an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, also known as disorders of gut-brain interaction. [22]